AI Week brings together the world AI community
Four days of events will feature keynotes and talks from leaders in AI and machine learning
EDMONTON, Alberta, April 14, 2022 (GLOBE NEWSWIRE) -- Amii (the Alberta Machine Intelligence Institute) has announced the program for AI Week, May 24-27 in Edmonton, Canada. With more than 20 events taking place across four days throughout the city, the celebration of Alberta’s AI excellence will feature an academic keynote from Richard S. Sutton, leading expert in reinforcement learning, who will discuss future research directions in the field.
The jam-packed week also includes panels on AI career paths for kids, AI for competitive advantage and the ethics of AI; a career and talent mixer connecting AI career seekers with top companies; and a full-day academic symposium bringing together the brightest minds in AI. The celebrations are rounded out by a ‘house’ party at a secret, soon-to-be-revealed location and the Amiiversary street party, marking 20 years of AI excellence in Alberta. Learn more about the program at www.ai-week.ca/program
“Over the past 20 years, Alberta has emerged as one of the world’s top destinations for AI research and application,” says Cam Linke, CEO of Amii. “With AI Week, we’re putting a global spotlight on the province and welcoming the world’s AI community to experience what many in the field have known for a long time: that Alberta is at the forefront of the AI revolution. AI Week isn’t just a celebration of 20 years of AI excellence – it’s a launching point for the next 20 years of advancement.”
AI Week has something for everyone – including sessions, networking events and socials for a range of ages and familiarity with AI. Additional keynotes will be delivered by Alona Fyshe, speaking about what brains and AI can tell us about one another, and Martha White, who will present on innovative applications of reinforcement learning. A special AI in Health keynote will highlight the work of Dornoosh Zonoobi and Jacob Jaremko of Medo.ai, which uses machine learning in concert with ultrasound technology to screen infants for hip dysplasia.
Informal networking and social events will help forge connections between members of the research, industry and innovation communities – as well as AI beginners and enthusiasts. Meanwhile, the Amiiversary street party, hosted on Rice Howard Way in Edmonton’s downtown core, will mark 20 years of AI excellence in Alberta. The party will be attended by the who’s-who of Edmonton AI, technology and innovation scenes.
AI Week will be attended by the world’s AI community, with over 500 applicants for travel bursaries from more than 35 different countries. The successful applicants, emerging researchers and industry professionals alike, will have the opportunity to learn alongside leaders in the field at the AI Week Academic Symposium, which is being organized by Amii’s Fellows from the University of Alberta, one of the world’s top academic institutions for AI research. The symposium will include talks and discussions among top experts in AI and machine learning as well as demos and lab showcases from the Amii community.
“I chose to set up in Canada in 2003 because, at the time, Alberta was one of the few places investing in building a community of AI researchers,” says Richard S. Sutton, Amii’s Chief Scientific Advisor, who is also a Professor at the University of Alberta and a Distinguished Research Scientist at DeepMind. “Nearly twenty years later, I am struck by how much we have achieved to advance the field of AI, not only locally but globally. AI Week is an opportunity to celebrate those achievements and showcase some of the brightest minds in AI.”
The event is being put on by Amii, one of Canada’s AI institutes in the Pan-Canadian AI Strategy and will feature event partners and community-led events from across Canada’s AI ecosystem. AI Week is made possible in part by our event partners and talent bursary sponsors: AltaML, Applied Pharmaceutical Innovation, ATB, Attabotics, BDC, CBRE, CIFAR, DeepMind, DrugBank, Explore Edmonton, NeuroSoph, RBC Royal Bank, Samdesk, TELUS and the University of Alberta.
One of Canada’s three centres of AI excellence as part of the Pan-Canadian AI Strategy, Amii (the Alberta Machine Intelligence Institute) is an Alberta-based non-profit institute that supports world-leading research in artificial intelligence and machine learning and translates scientific advancement into industry adoption. Amii grows AI capabilities through advancing leading-edge research, delivering exceptional educational offerings and providing business advice – all with the goal of building in-house AI capabilities. For more information, visit amii.ca.
Communications & Public Relations
t: 587.415.6100 ext. 109 | c: 780.991.7136
To view this piece of content from ml.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Mandalay Resources Corporation Announces the Results of Its Annual General Meeting of Shareholders25.5.2022 23:32:49 CEST | Press release
TORONTO, May 25, 2022 (GLOBE NEWSWIRE) -- Mandalay Resources Corporation ("Mandalay" or the "Company") (TSX: MND, OTCQB: MNDJF) is pleased to announce the results of its Annual General Meeting of Shareholders (the “Meeting”) held today virtually. All the resolutions presented at the Meeting were approved by the shareholders, with the votes cast by proxy representing 67.63% of the total shares outstanding as of the record date. Election of Directors The number of directors was fixed at seven members and each of the seven nominees listed in the Company’s Management Information Circular dated April 14, 2022, were re-elected to the Company’s Board of Directors. Abraham Jonker remains the lead independent director and Bradford Mills continues as Chair. Results of the votes cast by proxy are set out below. ResolutionVotes Cast by Proxy For% ForVotes Cast by Proxy Withheld% WithheldBradford A. Mills61,552,12099.95329,1930.047Abraham Jonker61,551,31399.95130,0000.049Amy Freedman61,547,53899.94
Galapagos to showcase commitment to rheumatoid arthritis care at the upcoming European League Against Rheumatism congress25.5.2022 22:01:00 CEST | Press release
Celebrating EULAR’s 75thanniversary with focus on a new era of rheumatoid arthritis care Mechelen, Belgium;25 May 2022, 22.01CET;Galapagos NV (Euronext & Nasdaq: GLPG) will present 11 abstracts at the European League Against Rheumatism (EULAR) congress 2022, 01-04 June, taking place in Copenhagen, Denmark. The broad range of abstracts include trial data analyses supporting the efficacy and safety profile of filgotinib andreal-world clinical data around alignment of prescribing between physicians and rheumatoid arthritis (RA) patients. Galapagos is also hosting a hybrid symposium: “Evolving patient care in RA: Can JAK inhibitors meet patient and physician expectations for RA treatment?”, which will include a discussion focused on aligning physician and patient treatment goals, looking at what is meant by ‘comprehensive care’ and how to ensure that people living with RA are part of treatment and care goal setting. A meet-the-expert session, “Patient-centred care in RA: cutting through th
trivago N.V. Announces Annual General Meeting of Shareholders25.5.2022 21:39:06 CEST | Press release
trivago N.V. (NASDAQ: TRVG) announced today that its annual general meeting of shareholders will be held on June 30, 2022 at the offices of NautaDutilh N.V., Beethovenstraat 400, 1082 PR Amsterdam, the Netherlands. The meeting will start at 3:00 p.m. CEST. The convening notice and explanatory notes for the general meeting are available free of charge in the Investor Relations section of trivago N.V.'s corporate website at ir.trivago.com. About trivago N.V. trivago is a leading global hotel search platform focused on reshaping the way travelers search for and compare hotels and alternative accommodations. Incorporated in 2005 in Düsseldorf, Germany, the platform allows travelers to make informed decisions by personalizing their hotel search and providing them access to a deep supply of hotel information and prices. trivago enables its advertisers to grow their businesses by providing access to a broad audience of travelers via its websites and apps. As of March 31, 2022, trivago has est
Correction: Changes in Nokia Corporation's own shares25.5.2022 19:20:00 CEST | Press release
Nokia Corporation Stock Exchange Release 25 May 2022 at 20:20 EEST Correction: Changes in Nokia Corporation's own shares Espoo, Finland – This is a correction to "Changes in Nokia Corporation's own shares" stock exchange release that was published today at 19:30 EEST. A total of 183 965 Nokia shares (NOKIA) held by the company were today transferred without consideration to participants of Nokia's equity-based incentive plans in accordance with the rules of the plans. The transfer is based on the resolution of the Board of Directors to issue shares held by the company to settle its commitments to participants of the plans as announced on 3 February 2022. The number of own shares held by Nokia Corporation following the transfer is 61 262 561. This version is otherwise identical but now includes an updated total number of Nokia shares transferred (incorrect number was 188 636). About Nokia At Nokia, we create technology that helps the world act together. As a trusted partner for critical
Ultimovacs’ Clinical Data in Journal for ImmunoTherapy of Cancer Show Long-term Dynamic T Cell Responses with UV1 and Checkpoint Inhibitor Synergy25.5.2022 18:45:00 CEST | Press release
Data from three trials of UV1 show dynamic T cell responses, lasting up to 7.5 years UV1-specific immune responses associated with longer clinical survivalSynergy between UV1 vaccination and checkpoint inhibition Oslo, 25 May2022: Ultimovacs ASA ("Ultimovacs") (OSE ULTI), a clinical stage leader in immune stimulatory vaccines for cancer, announced the publication of long-term follow-up data on UV1 in the Journal for ImmunoTherapy of Cancer (JITC). The data show that dynamic UV1 specific immune responses last up to 7.5 years, are associated with longer survival and are enhanced when UV1 is used in combinations with checkpoint inhibitors. “It is important to be able to share this validating data with our research and clinical colleagues through JITC. The data demonstrate highly durable UV1-induced immune responses that are associated with substantially longer overall survival and boosted by checkpoint inhibitors. This is strong support for Ultimovacs’ broad Phase II program combining UV1